Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Allogene Therapeutics (ALLO) been one of those stocks this year? A quick glance ...

The last time I wrote about Allogene Therapeutics, Inc. (ALLO) it was in a Seeking Alpha article entitled "Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products." I noted the ...

(TNS) — Thousands of students across Lincoln will soon be able to access their online homework assignments and class materials from anywhere in Lincoln, regardless of whether their home has Internet.

LINCOLN, Neb. (KOLN) - ALLO Fiber has officially launched its Smart Schools initiative in partnership with Lincoln Public Schools — a program designed to help students stay connected and engaged in ...

Upload star Andy Allo initially had a hard time accepting how her character, Nora, ends the series — but eventually came around to seeing showrunner Greg Daniels’ “genius.” Warning: Spoilers below for ...

I maintain a 'Buy' rating on Allogene Therapeutics, as their diverse allogeneic cell therapy pipeline shows encouraging early data and pivotal trials are progressing. ALLO's financial position remains ...

TEMPO.CO, Jakarta - PT Allo Bank Indonesia Tbk (BBHI) has announced that Indra Utoyo has stepped down from his role as CEO. According to Acting CEO Ari Yanuanto Asah, Indra’s resignation is connected ...

LINCOLN, Neb. (KOLN) - ALLO Fiber reduced its workforce by 9% across the six states it serves on Wednesday. The internet provider told 10/11 News that less than 70 employees in 40 Nebraska communities ...

Elson is the co-host of the 'Prof G Markets' podcast with Scott Galloway, and the 'First Time Founders' podcast. By Caitlin Huston Business Writer CAA has signed business analyst, writer and podcast ...

Prof. Mark Wolters is a Teaching Associate Professor of Business Administration at Gies College of Business at the University of Illinois at Urbana Champaign. He has been a faculty member at the U of ...

ALLO-316 shows promising response rates in advanced renal cell carcinoma, utilizing Dagger technology for enhanced CAR T cell efficacy. Allogene Therapeutics has announced promising data from its ...